Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection
- 1 December 1989
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 57 (1) , 23-28
- https://doi.org/10.1016/0378-5173(89)90259-7
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A direct comparison of sodium stibogluconate treatment in two animal models of human visceral leishmaniasis, mouse and hamsterInternational Journal of Pharmaceutics, 1989
- Visceral leishmaniasis: Resistance to reinfection in the liver following chemotherapy in the BALB/c mouseExperimental Parasitology, 1989
- Visceral Leishmaniasis: Drug Carrier System Characteristics and the Ability to Clear Parasites from the Liver, Spleen and Bone Marrow in Leishmania donovani Infected BALB/c MiceJournal of Pharmacy and Pharmacology, 1989
- The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependentJournal of Pharmacy and Pharmacology, 1988
- Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral LeishmaniasisJournal of Pharmacy and Pharmacology, 1988
- Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconateJournal of Pharmacy and Pharmacology, 1987
- Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconateJournal of Pharmacy and Pharmacology, 1986
- Liposomes as drug carriers in leishmaniasis and malariaParasitology Today, 1986
- The preparation and properties of niosomes—non-ionic surfactant vesiclesJournal of Pharmacy and Pharmacology, 1985
- Fusion of Host Cell Secondary Lysosomes with the Parasitophorous Vacuoles of Leishmania mexicana‐inlected MacrophagesThe Journal of Protozoology, 1975